The companies have signed a letter of intent to enter into co-marketing and technology development option agreement to utilize Zogenix’s DosePro needle-free drug delivery technology for new commercial out-licensing opportunities.
The Letter of Intent contemplates that upon successful out-licensing of DosePro, Battelle will have the option to participate directly in further development of the DosePro technology.
DosePro technology enables needle-free medication delivery under the skin.
DosePro technology uses a small amount of compressed gas to deliver a liquid formulation through the skin as a thin jet of medication.
Zogenix DosePro Technology vice president and general manager John Turanin said that DosePro can provide sustainable competitive advantages for many injectable drugs, especially biologics.